Onco-NX Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Onco-NX General Information

Description

Operator of a drug development company headquartered in Manchester, England. The company engages in the development of drugs and medicines to detect cancerous tumor cells.

Contact Information

Website
www.onco-nx.com
Formerly Known As
Friars 656 Limited
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Incanthera Limited
  • 76 King Street
  • Manchester M2 4NH
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Incanthera Limited
  • 76 King Street
  • Manchester M2 4NH
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Onco-NX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 11-Mar-2014 Completed Startup
2. Early Stage VC 09-Nov-2011 Completed Startup
1. University Spin-Out 07-Apr-2011 Completed Startup
To view Onco-NX’s complete valuation and funding history, request access »

Onco-NX Patents

Onco-NX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2662917-T3 Quinone compounds and their uses for cancer treatment Active 30-Jul-2012
AU-2013298653-A1 Quinone compounds and their uses for the treatment of cancer Active 30-Jul-2012
AU-2013298653-B2 Quinone compounds and their uses for the treatment of cancer Inactive 30-Jul-2012
CA-2880021-A1 Quinone compounds and their uses for the treatment of cancer Active 30-Jul-2012
EP-2882743-A1 Quinone compounds and their uses for the treatment of cancer Active 30-Jul-2012 C07D203/14
To view Onco-NX’s complete patent history, request access »

Onco-NX Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Spark Impact Corporate Venture Capital Minority
To view Onco-NX’s complete investors history, request access »

Onco-NX FAQs

  • When was Onco-NX founded?

    Onco-NX was founded in 2011.

  • Where is Onco-NX headquartered?

    Onco-NX is headquartered in Manchester, United Kingdom.

  • What industry is Onco-NX in?

    Onco-NX’s primary industry is Drug Discovery.

  • Is Onco-NX a private or public company?

    Onco-NX is a Private company.

  • What is Onco-NX’s current revenue?

    The current revenue for Onco-NX is .

  • How much funding has Onco-NX raised over time?

    Onco-NX has raised $79.6K.

  • Who are Onco-NX’s investors?

    Spark Impact has invested in Onco-NX.

  • When was Onco-NX acquired?

    Onco-NX was acquired on 11-Mar-2014.

  • Who acquired Onco-NX?

    Onco-NX was acquired by Incanthera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process